Overview

Glasdegib Renal Impairment Study

Status:
Completed
Trial end date:
2018-09-19
Target enrollment:
Participant gender:
Summary
The goal of this study is to administer single dose (100 mg) glasdegib tablet to subjects with normal, moderate and severe renal impairment and estimate the effect, if any, of this renal impairment on glasdegib pharmacokinetics.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer